Literature DB >> 21421002

Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate.

F O Eko1, D N Okenu, U P Singh, Q He, C Black, J U Igietseme.   

Abstract

The need to simultaneously target infections with epidemiological overlap in the population with a single vaccine provides the basis for developing combination vaccines. Vibrio cholerae ghosts (rVCG) offer an attractive approach for developing vaccines against a number of human and animal pathogens. In this study, we constructed a multisubunit vaccine candidate co-expressing the serovar D-derived Porin B and polymorphic membrane protein-D proteins of Chlamydia trachomatis and evaluated its ability to simultaneously induce broad-based chlamydial immunity and elicit a vibriocidal antibody response to the Vibrio carrier envelope. Intramuscular (IM) immunization with the vaccine candidate elicited high levels of antigen-specific genital mucosal and systemic Th1 cell-mediated and humoral immune responses against heterologous serovars and strains, including serovars E-H and L. Also, in addition to the multisubunit vaccine, the single subunit constructs conferred significant cross protection against the heterologous mouse strain, Chlamydia muridarum. Furthermore, all mice immunized with rVCG vaccine constructs responded with a significant rise in vibriocidal antibody titer, the surrogate marker for protection in cholera. These findings demonstrate the ability of the multisubunit vaccine to induce cross protective chlamydial as well as vibriocidal immunity and establish the possibility of developing a broadly efficacious Chlamydia-cholera combination vaccine.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21421002      PMCID: PMC3084325          DOI: 10.1016/j.vaccine.2011.03.027

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  53 in total

Review 1.  Antibody regulation of Tcell immunity: implications for vaccine strategies against intracellular pathogens.

Authors:  Joseph U Igietseme; Francis O Eko; Qing He; Carolyn M Black
Journal:  Expert Rev Vaccines       Date:  2004-02       Impact factor: 5.217

2.  Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease.

Authors:  M Jertborn; A M Svennerholm; J Holmgren
Journal:  J Clin Microbiol       Date:  1986-08       Impact factor: 5.948

3.  Prophylactic significance of the nonlipopolysaccharide antigens of Vibrio cholerae.

Authors:  S R Attridge; D Rowley
Journal:  J Infect Dis       Date:  1983-11       Impact factor: 5.226

4.  Chlamydia trachomatis polymorphic membrane protein D is a species-common pan-neutralizing antigen.

Authors:  Deborah D Crane; John H Carlson; Elizabeth R Fischer; Patrik Bavoil; Ru-ching Hsia; Chun Tan; Cho-chou Kuo; Harlan D Caldwell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-30       Impact factor: 11.205

5.  A novel recombinant multisubunit vaccine against Chlamydia.

Authors:  Francis O Eko; Qing He; Teresa Brown; Lucinda McMillan; Godwin O Ifere; Godwin A Ananaba; Deborah Lyn; Werner Lubitz; Kathryn L Kellar; Carolyn M Black; Joseph U Igietseme
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

6.  Immune response to the Chlamydia trachomatis outer membrane protein PorB.

Authors:  Diane E Kawa; Julius Schachter; Richard S Stephens
Journal:  Vaccine       Date:  2004-10-22       Impact factor: 3.641

7.  From the inside out--processing of the Chlamydial autotransporter PmpD and its role in bacterial adhesion and activation of human host cells.

Authors:  Wolfgang Wehrl; Volker Brinkmann; Peter R Jungblut; Thomas F Meyer; Agnes J Szczepek
Journal:  Mol Microbiol       Date:  2004-01       Impact factor: 3.501

8.  Evaluation of the protective efficacy of Vibrio cholerae ghost (VCG) candidate vaccines in rabbits.

Authors:  Francis O Eko; Tatiana Schukovskaya; E Y Lotzmanova; V V Firstova; N V Emalyanova; S N Klueva; A L Kravtzov; L F Livanova; Vladimir V Kutyrev; Joseph U Igietseme; Werner Lubitz
Journal:  Vaccine       Date:  2003-09-08       Impact factor: 3.641

9.  Polymorphic membrane protein (PMP) 20 and PMP 21 of Chlamydia pneumoniae induce proinflammatory mediators in human endothelial cells in vitro by activation of the nuclear factor-kappaB pathway.

Authors:  Alexander Niessner; Christoph Kaun; Gerlinde Zorn; Walter Speidl; Zeynep Türel; Gunna Christiansen; Anna-Sofie Pedersen; Svend Birkelund; Susan Simon; Apostolos Georgopoulos; Wolfgang Graninger; Rainer de Martin; Joachim Lipp; Bernd R Binder; Gerald Maurer; Kurt Huber; Johann Wojta
Journal:  J Infect Dis       Date:  2003-06-12       Impact factor: 5.226

10.  Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up.

Authors:  J D Clemens; D A Sack; J R Harris; F Van Loon; J Chakraborty; F Ahmed; M R Rao; M R Khan; M Yunus; N Huda
Journal:  Lancet       Date:  1990-02-03       Impact factor: 79.321

View more
  11 in total

Review 1.  Genital Chlamydia trachomatis: understanding the roles of innate and adaptive immunity in vaccine research.

Authors:  Sam Vasilevsky; Gilbert Greub; Denise Nardelli-Haefliger; David Baud
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

Review 2.  Update on Chlamydia trachomatis Vaccinology.

Authors:  Luis M de la Maza; Guangming Zhong; Robert C Brunham
Journal:  Clin Vaccine Immunol       Date:  2017-04-05

Review 3.  Dendritic cells and vaccine design for sexually-transmitted diseases.

Authors:  Dorothee Duluc; Julien Gannevat; Hyemee Joo; Ling Ni; Katherine Upchurch; Muriel Boreham; Michael Carley; Jack Stecher; Gerard Zurawski; Sangkon Oh
Journal:  Microb Pathog       Date:  2012-11-29       Impact factor: 3.738

4.  CD4+ T cells are necessary and sufficient to confer protection against Chlamydia trachomatis infection in the murine upper genital tract.

Authors:  David C Gondek; Andrew J Olive; Georg Stary; Michael N Starnbach
Journal:  J Immunol       Date:  2012-08-01       Impact factor: 5.422

5.  Rectal administration of a chlamydial subunit vaccine protects against genital infection and upper reproductive tract pathology in mice.

Authors:  Roshan Pais; Yusuf Omosun; Qing He; Uriel Blas-Machado; Carolyn Black; Joseph U Igietseme; Kohtaro Fujihashi; Francis O Eko
Journal:  PLoS One       Date:  2017-06-01       Impact factor: 3.240

6.  Chlamydia abortus Pmp18.1 Induces IL-1β Secretion by TLR4 Activation through the MyD88, NF-κB, and Caspase-1 Signaling Pathways.

Authors:  Qing Pan; Qiang Zhang; Jun Chu; Roshan Pais; Shanshan Liu; Cheng He; Francis O Eko
Journal:  Front Cell Infect Microbiol       Date:  2017-12-18       Impact factor: 5.293

7.  Immunization with dendritic cells pulsed ex vivo with recombinant chlamydial protease-like activity factor induces protective immunity against genital chlamydiamuridarum challenge.

Authors:  Weidang Li; Ashlesh K Murthy; B K R Chaganty; M Neal Guentzel; J Seshu; James P Chambers; Guangming Zhong; Bernard P Arulanandam
Journal:  Front Immunol       Date:  2011-12-08       Impact factor: 7.561

8.  Escherichia coli Nissle 1917 bacterial ghosts retain crucial surface properties and express chlamydial antigen: an imaging study of a delivery system for the ocular surface.

Authors:  Jacqueline Montanaro; Aleksandra Inic-Kanada; Angela Ladurner; Elisabeth Stein; Sandra Belij; Nora Bintner; Simone Schlacher; Nadine Schuerer; Ulrike Beate Mayr; Werner Lubitz; Nikolaus Leisch; Talin Barisani-Asenbauer
Journal:  Drug Des Devel Ther       Date:  2015-07-21       Impact factor: 4.162

Review 9.  Immunity, immunopathology, and human vaccine development against sexually transmitted Chlamydia trachomatis.

Authors:  Jose Rey-Ladino; Allen G P Ross; Allan W Cripps
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

10.  Cellular Basis for the Enhanced Efficacy of the Fms-Like Tyrosine Kinase 3 Ligand (FL) Adjuvanted VCG-Based Chlamydia abortus Vaccine.

Authors:  Shakyra Richardson; Fnu Medhavi; Tayhlor Tanner; Stephanie Lundy; Yusuf Omosun; Joseph U Igietseme; Darin Carroll; Francis O Eko
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.